Trials / Completed
CompletedNCT00033202
This is an Early Study to Investigate the Effect of Gimatecan® in Adults With Solid Tumor
Phase I Study of Oral ST1481 Administered Once Weekly Every 3 Out 4 Weeks in Patients With Advanced Solid Malignancies.
- Status
- Completed
- Phase
- Phase 1
- Study type
- Interventional
- Enrollment
- 30 (estimated)
- Sponsor
- Sigma-Tau Research, Inc. · Industry
- Sex
- All
- Age
- 18 Years
- Healthy volunteers
- Not accepted
Summary
Gimatecan® is sigma-tau Research's new, potent, oral Topoisomerase I inhibitor. Drugs in this class play a crucial role in destroying DNA replication in tumors. We are conducting this study to determine the Maximum Tolerated Dose of our compound, when given as a capsule, rather than by intravenous injection.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | Gimatecan® (ST-1481) |
Timeline
- Start date
- 2002-03-01
- Completion
- 2005-02-01
- First posted
- 2002-04-10
- Last updated
- 2009-06-03
Locations
3 sites across 1 country: United States
Source: ClinicalTrials.gov record NCT00033202. Inclusion in this directory is not an endorsement.